Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 1
1996 1
1997 1
1998 1
1999 4
2000 3
2001 2
2002 1
2003 2
2004 3
2005 3
2006 3
2007 9
2008 9
2009 8
2010 5
2011 9
2012 13
2013 8
2014 18
2015 19
2016 17
2017 18
2018 16
2019 17
2020 22
2021 14
2022 15
2023 8
2024 12
2025 19
2026 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

251 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Awan FT, Gamse JT, Overdijk MB, Breij ECW, Jure-Kunkel M, Sanghavi K, Brady LK, Guan M, Verbrugge I, Chen J, Gong N, Gillespie M, Tees M, Gallogly M, Hutchings M, Christensen JH, Sureda A, Cordoba R, Ahmed S, Woei-A-Jin FJSH, Abrisqueta P, Giné E, Roost Clausen M, Bhat SA, Gopal AK, Chamuleau MED. Awan FT, et al. Among authors: gopal ak. J Immunother Cancer. 2026 Jul 7;14(7):e014311. doi: 10.1136/jitc-2025-014311. J Immunother Cancer. 2026. PMID: 42413982 Free PMC article. Clinical Trial.
GEN3009 was assessed in non-clinical studies and a phase 1 dose-escalation study of B-cell non-Hodgkin's lymphoma (B-NHL). METHODS: After a non-clinical toxicity study was conducted in cynomolgus monkeys, a phase 1, first-in-human, open-label, multicenter dose-escal …
GEN3009 was assessed in non-clinical studies and a phase 1 dose-escalation study of B-cell non-Hodgkin's lymphoma (B-NHL). MET …
Autologous transplant for patients with chemotherapy-sensitive late relapse of diffuse large B-cell lymphoma.
Iovino L, Ma N, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Hamadani M, Riedell PA, Gopal AK, Holmberg L, Wu QV, Smith SM, Shadman M. Iovino L, et al. Among authors: gopal ak. Blood Neoplasia. 2026 Apr 25;3(3):100240. doi: 10.1016/j.bneo.2026.100240. eCollection 2026 Aug. Blood Neoplasia. 2026. PMID: 42317600 Free PMC article.
In the era of chimeric antigen receptor (CAR) T-cell therapy, autologous stem cell transplant (ASCT) for diffuse large B-cell lymphoma (DLBCL) is preferentially offered to patients with late relapse (>12 months) who achieve complete or partial response (CR or PR, respec …
In the era of chimeric antigen receptor (CAR) T-cell therapy, autologous stem cell transplant (ASCT) for diffuse large B-cell lymphoma …
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.
Smith SD, Sundaram S, Giri S, Ness A, Wang Y, Gopal AK, Pang Y, Tatoian ET, Grossfeld T, Lynch RC, Warren EH, Nowakowski GS, Park SI. Smith SD, et al. Among authors: gopal ak. Am J Hematol. 2026 Jun 17. doi: 10.1002/ajh.70406. Online ahead of print. Am J Hematol. 2026. PMID: 42305039
First-line therapy for mantle cell lymphoma (MCL) represents a critical opportunity for clinical benefit via sustained complete response. ...
First-line therapy for mantle cell lymphoma (MCL) represents a critical opportunity for clinical benefit via sustained complete respo …
"Immunologic Dream Team": BiTEs peri-allotransplant to redirect donor lymphocytes towards GVL.
Iovino L, Shadman M, Milano F, Gopal AK. Iovino L, et al. Among authors: gopal ak. Blood Adv. 2026 May 20:bloodadvances.2026020530. doi: 10.1182/bloodadvances.2026020530. Online ahead of print. Blood Adv. 2026. PMID: 42160762
Bispecific T cell engagers (BiTEs) provide high rates of responses in patients with relapsed and refractory B cell lymphomas and multiple myeloma otherwise resistant to other therapies, but unfortunately the duration of response to these treatments is limited in time. ...H …
Bispecific T cell engagers (BiTEs) provide high rates of responses in patients with relapsed and refractory B cell lymphomas and mult …
Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.
Baek G, Varma G, Yamshon S, van Besien H, Bartlett NL, Watkins M, Shah HR, Baron K, Merryman RW, Falade AS, Svoboda J, Prischak S, D'Angelo C, Lukowski JD, Advani RH, Yeung AH, Rosenberg M, Voutsinas J, Di M, Lynch R, Poh C, Raghunathan V, Shadman M, Smith S, Till BG, Ujjani C, Diefenbach CS, Gopal AK. Baek G, et al. Among authors: gopal ak. Blood Adv. 2026 May 26;10(10):3565-3571. doi: 10.1182/bloodadvances.2025018267. Blood Adv. 2026. PMID: 41855500 Free PMC article.
Biomarkers Informed by Single-Cell and Spatial Transcriptomics-Biomarkers for Grade 3 Follicular Lymphoma.
Kanzaria A, Arora S, Naik A, Dhanushkodi N, Ho CC, Kaur N, Zhang J, Ren X, Fromm JR, Shadman M, Smith S, Gopal A, Roncador G, Holland E, Naresh KN. Kanzaria A, et al. Among authors: gopal a. Mod Pathol. 2026 Mar;39(3):100958. doi: 10.1016/j.modpat.2026.100958. Epub 2026 Jan 9. Mod Pathol. 2026. PMID: 41521011
Follicular lymphoma (FL) patients have variable outcomes, underscoring the need for biomarkers for improved risk stratification. ...
Follicular lymphoma (FL) patients have variable outcomes, underscoring the need for biomarkers for improved risk stratification. ...
HIV, HBV, and HCV Testing in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Experience From a Comprehensive Cancer Center.
Kwendakwema CN, Lan KF, Kim HN, Gopal AK, Menon MP. Kwendakwema CN, et al. Among authors: gopal ak. Clin Lymphoma Myeloma Leuk. 2026 Apr;26(4):e536-e541. doi: 10.1016/j.clml.2025.12.010. Epub 2025 Dec 14. Clin Lymphoma Myeloma Leuk. 2026. PMID: 41494888
PURPOSE: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype non-Hodgkin lymphoma. HIV, hepatitis B (HBV), and hepatitis C (HCV) infections are DLBCL risk factors. ...
PURPOSE: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype non-Hodgkin lymphoma. HIV, hepatitis B (HBV), and he …
Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma.
Ho C, Kennedy N, Di M, Gopal AK, Lynch RC, Ng K, Wu QV, Poh C, Raghunathan V, Rasmussen H, Shadman M, Till BG, Ujjani CS, Smith SD. Ho C, et al. Among authors: gopal ak. Clin Lymphoma Myeloma Leuk. 2026 Mar;26(3):e367-e375. doi: 10.1016/j.clml.2025.11.002. Epub 2025 Nov 4. Clin Lymphoma Myeloma Leuk. 2026. PMID: 41285650 Free article.
BACKGROUND: Frontline therapy fails to cure 25% of patients with large B-cell lymphoma (LBCL), underscoring the need for clinical trials to improve outcomes. However, enrollment remains limited by logistical and structural barriers. ...METHODS: We retrospectively reviewe …
BACKGROUND: Frontline therapy fails to cure 25% of patients with large B-cell lymphoma (LBCL), underscoring the need for clinical t …
251 results